Clinical Trial Results:
Phase II study of the mTOR-Inhibitor EVEROLIMUS as
maintenance therapy in patients aged over 60 years with Mantle
Cell Lymphoma (MCL) after first, second, third or fourth line
chemotherapy
New title since Protocol Version 4.0
Phase II study of the mTOR-Inhibitor EVEROLIMUS as
maintenance therapy in patients aged over 60 years with Mantle
Cell Lymphoma (MCL) after first, second, third or fourth line
chemotherapy
Summary
|
|
EudraCT number |
2007-005116-12 |
Trial protocol |
DE |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
04 Nov 2020
|
First version publication date |
09 Feb 2020
|
Other versions |
v1 |
Version creation reason |
|
Summary report(s) |
CSR_CRAD |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.